Brought to you by 
AbbVie, Mission Therapeutics Team up in the Neurology Space; $20M Milestone Payment Reached
09 Aug 2021
Executive Summary
Mission Therapeutics Ltd. is teaming up with AbbVie Inc. in the research and preclinical development of specified deubiquitylating (DUB) enzyme inhibitors for treating Alzheimer’s and Parkinson’s diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie, Mission Therapeutics Team up in the Neurology Space; $20M Milestone Payment Reached
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice